These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 16808678)
1. Brimonidine 0.2% versus brimonidine Purite 0.15%: prophylactic effect on iop elevation after Nd:YAG laser posterior capsulotomy. Yeom HY; Lee JH; Hong YJ; Seong GJ J Ocul Pharmacol Ther; 2006 Jun; 22(3):176-81. PubMed ID: 16808678 [TBL] [Abstract][Full Text] [Related]
2. Effect of 0.2% brimonidine in preventing intraocular pressure elevation after Nd:YAG laser posterior capsulotomy. Seong GJ; Lee YG; Lee JH; Lim SJ; Lee SC; Hong YJ; Kwon OW; Kim HB Ophthalmic Surg Lasers; 2000; 31(4):308-14. PubMed ID: 10928668 [TBL] [Abstract][Full Text] [Related]
3. Use of topical brimonidine to prevent intraocular pressure elevations following Nd:YAG-laser posterior capsulotomy. Gartaganis SP; Mela EK; Katsimpris JM; Petropoulos JK; Karamanos NK; Koliopoulos JX Ophthalmic Surg Lasers; 1999; 30(8):647-52. PubMed ID: 10507567 [TBL] [Abstract][Full Text] [Related]
4. Bimatoprost 0.03% versus brimonidine 0.2% in the prevention of intraocular pressure spike following neodymium:yttrium–aluminum–garnet laser posterior capsulotomy. Artunay O; Yuzbasioglu E; Unal M; Rasier R; Sengul A; Bahcecioglu H J Ocul Pharmacol Ther; 2010 Oct; 26(5):513-7. PubMed ID: 20874499 [TBL] [Abstract][Full Text] [Related]
5. Apraclonidine 0.5% versus brimonidine 0.2% for the control of intraocular pressure elevation following anterior segment laser procedures. Chevrier RL; Assalian A; Duperré J; Lesk MR Ophthalmic Surg Lasers; 1999 Mar; 30(3):199-204. PubMed ID: 10100253 [TBL] [Abstract][Full Text] [Related]
6. Fixed combination brimonidine-timolol versus brimonidine for treatment of intraocular pressure elevation after neodymium:YAG laser posterior capsulotomy. Öner V; Alakuş MF; Taş M; Türkyılmaz K; Işcan Y J Ocul Pharmacol Ther; 2012 Dec; 28(6):576-80. PubMed ID: 22809091 [TBL] [Abstract][Full Text] [Related]
7. Brinzolamide 1% versus apraclonidine 0.5% to prevent intraocular pressure elevation after neodymium:YAG laser posterior capsulotomy. Unal M; Yücel I; Akar Y J Cataract Refract Surg; 2006 Sep; 32(9):1499-502. PubMed ID: 16931262 [TBL] [Abstract][Full Text] [Related]
8. The prophylactic effect of betaxolol 0.5% versus brimonidine 0.2% on IOP elevation after Nd:YAG laser posterior capsulotomy. Elmi Sadr N; Saber E; Paknazar F Clin Exp Optom; 2022 Nov; 105(8):813-816. PubMed ID: 34753412 [TBL] [Abstract][Full Text] [Related]
9. Brimonidine 0.15% versus apraclonidine 0.5% for prevention of intraocular pressure elevation after anterior segment laser surgery. Chen TC J Cataract Refract Surg; 2005 Sep; 31(9):1707-12. PubMed ID: 16246772 [TBL] [Abstract][Full Text] [Related]
10. Prophylactic use of timolol maleate to prevent intraocular pressure elevation after Nd-YAG laser posterior capsulotomy. Cai JP; Cheng JW; Wei RL; Ma XY; Jiang F; Zhu H; Li Y Int Ophthalmol; 2008 Feb; 28(1):19-22. PubMed ID: 17585375 [TBL] [Abstract][Full Text] [Related]
11. Topical 2.0% dorzolamide vs oral acetazolamide for prevention of intraocular pressure rise after neodymium:YAG laser posterior capsulotomy. Ladas ID; Baltatzis S; Panagiotidis D; Zafirakis P; Kokolakis SN; Theodossiadis GP Arch Ophthalmol; 1997 Oct; 115(10):1241-4. PubMed ID: 9338667 [TBL] [Abstract][Full Text] [Related]
12. Brimonidine 0.2% versus apraclonidine 0.5% for prevention of intraocular pressure elevations after anterior segment laser surgery. Chen TC; Ang RT; Grosskreutz CL; Pasquale LR; Fan JT Ophthalmology; 2001 Jun; 108(6):1033-8. PubMed ID: 11382625 [TBL] [Abstract][Full Text] [Related]
14. The effect of 0.25% apraclonidine in preventing intraocular pressure elevation after Nd:YAG laser posterior capsulotomy. Simsek S; Ertürk H; Demirok A; Cinal A; Yasar T; Karadenizli C Eur J Ophthalmol; 1998; 8(3):167-72. PubMed ID: 9793771 [TBL] [Abstract][Full Text] [Related]
15. [Efficacy of topic ocular hipotensive agents after posterior capsulotomy]. Minello AA; Prata Junior JA; Mello PA Arq Bras Oftalmol; 2008; 71(5):706-10. PubMed ID: 19039468 [TBL] [Abstract][Full Text] [Related]
16. Long-term elevation of intraocular pressure after neodymium: YAG laser posterior capsulotomy. Jahn CE; Emke M Ophthalmologica; 1996; 210(2):85-9. PubMed ID: 9148259 [TBL] [Abstract][Full Text] [Related]
17. A 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension. Mundorf T; Williams R; Whitcup S; Felix C; Batoosingh A J Ocul Pharmacol Ther; 2003 Feb; 19(1):37-44. PubMed ID: 12648302 [TBL] [Abstract][Full Text] [Related]
18. Brimonidine-purite 0.1% versus brimonidine-purite 0.15% twice daily in glaucoma or ocular hypertension: a 12-month randomized trial. Cantor LB; Safyan E; Liu CC; Batoosingh AL Curr Med Res Opin; 2008 Jul; 24(7):2035-43. PubMed ID: 18534052 [TBL] [Abstract][Full Text] [Related]
19. 24-hour intraocular pressures with brimonidine purite versus dorzolamide added to latanoprost in primary open-angle glaucoma subjects. Konstas AG; Karabatsas CH; Lallos N; Georgiadis N; Kotsimpou A; Stewart JA; Stewart WC Ophthalmology; 2005 Apr; 112(4):603-8. PubMed ID: 15808251 [TBL] [Abstract][Full Text] [Related]
20. Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension. Day DG; Hollander DA Curr Med Res Opin; 2008 May; 24(5):1435-42. PubMed ID: 18402717 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]